Advertisement
Australia markets close in 3 hours 5 minutes
  • ALL ORDS

    7,768.70
    -130.20 (-1.65%)
     
  • ASX 200

    7,518.70
    -123.40 (-1.61%)
     
  • AUD/USD

    0.6382
    -0.0044 (-0.68%)
     
  • OIL

    86.07
    +3.34 (+4.04%)
     
  • GOLD

    2,419.90
    +21.90 (+0.91%)
     
  • Bitcoin AUD

    96,163.41
    -761.43 (-0.79%)
     
  • CMC Crypto 200

    1,241.26
    +355.72 (+37.22%)
     
  • AUD/EUR

    0.6005
    -0.0026 (-0.43%)
     
  • AUD/NZD

    1.0875
    +0.0000 (+0.00%)
     
  • NZX 50

    11,745.11
    -90.93 (-0.77%)
     
  • NASDAQ

    17,394.31
    -99.31 (-0.57%)
     
  • FTSE

    7,877.05
    +29.06 (+0.37%)
     
  • Dow Jones

    37,775.38
    +22.07 (+0.06%)
     
  • DAX

    17,837.40
    +67.38 (+0.38%)
     
  • Hang Seng

    16,092.63
    -293.24 (-1.79%)
     
  • NIKKEI 225

    36,818.81
    -1,260.89 (-3.31%)
     

23andMe Stock Could Be a Big Winner If This 1 Thing Happens

In June, 23andMe (NASDAQ: ME) officially finished the process of going public via a special purpose acquisition company (SPAC). While no one knows where shares of the genetic-testing company will trade in the near term, investors have a better idea of where 23andMe stock can trade over the long term. Over the course of years, stock prices tend to correlate with cash flows and, therefore, if the company dramatically increases it cash flows, the stock price could head higher as well.